Background

Dr. George H. Poste, D.V.M., Ph.D., F.R.C.Path, F.R.S. serves as a Senior Technical Advisor of Caris, Ltd. Dr. Poste has been the Chief Executive Officer at Health Technology Networks since 1999. Dr. Poste is Special Limited Partner at Care Capital LLC. He has been the Chief Scientist of Complex Adaptive Systems Initiative (CASI) at Arizona State University since February 2009. He serves as Professor of Complex Adaptive Systems Initiative at Arizona State University. ... He also serves as the Vice Chairman and Chief Scientific Advisor at Caris Life Sciences Inc. He founded the Boidesign Institute at ASU and was with it from 2003 to 2008. In creating this Institute, he designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $225 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. From 1992 to 1999, he served as the Chief Science and Technology Officer and President of R&D at SmithKline Beecham (SB) and held other positions at it or at its related entities. During his tenure at SmithKline Beecham he was associated with the successful registration of 31 drug, vaccine, and diagnostic products. He serves as a Non-Executive Chairman of Orchid BioSciences, Inc. He has been the Non-Executive Chairman of Structural GenomiX, Inc. since 2000. He serves as the Chairman of Scientific Advisory Board at Archemix Corp. He served as Non-Executive Chairman of Caris Molecular Diagnostics since August 2008. He served as Chairman of the Board at SGX Pharmaceuticals, Inc., and Cerebrus Pharmaceuticals Limited. He served as the Non-Executive Chairman of diaDexus since September 1997. He served as the Chairman on the Boards of Maxygen, Inc. and Illumina, Inc. He served as Chairman of the Board at Orchid Cellmark Inc. from 2002 to August 25, 2009. He serves as Vice Chairman of Miraca Life Sciences, Inc. He has been a Director of Exelixis, Inc. since August 2004; and Orchid Biosciences Inc. since March 2000. He serves as the Member of the Clinical, Scientific, and Business Advisory Board of Human Longevity, Inc. He has been a Director of Monsanto Company since February 2003. He serves as Member of Advisory Board at Burrill Biotechnology Capital Fund I, L.P., Burrill Life Sciences Capital Fund III, L.P. and Burrill Biotechnology Capital Fund II, L.P. He has been an Outside Director of Caris Life Sciences, Inc., since November 2006. He serves as a Member of Scientific Advisory Board at Synthetic Genomics, Inc. and Anacor Pharmaceuticals, Inc., and Boston BioCom LLC. He serves as Member of the Editorial Advisory Board at RJ Communications and Media Ltd. He chairs the Department of Defense Task Force on the Protection of the United States against Bioterrorism and heads Arizona State University’s newly chartered Arizona Biodesign Institute as its Director. He served as a Director and Member of Scientific Advisory Board at Molecular Profiling Institute. He served as a Director of CaremarkPCS, LLC and AdvancePCS since July 2002. He served as Director of Anacor Pharmaceuticals, and CMDx. He served as Director at Orchid Cellmark Inc. from March 2000 to August 25, 2009, Caremark Rx, L.L.C. since March 24, 2004 and Special Limited Partner since July 2002. He served as a Director of SmithKline Beecham Ltd. He is a Co-Founder of Cancer and editorial board Metastasis Reviews and Advanced Drug Delivery Reviews, a Past Chairman of the journal, Nature BioTechnology, serves on the editorial boards of several journals and also writes a regular column for the Financial Times. He is a Research Professor at the University of Pennsylvania, the William Pitt Fellow at Pembroke College, Cambridge University, and a Fellow of University College, London. He is also a Regents' Professor and Del E. Webb Distinguished Professor of Biology at Arizona State University, Skysong. He is a Board Certified Pathologist, a Fellow of the Royal Society and Royal College of Pathologists, a distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He is also a Founder Fellow of the Academy of Medical Sciences in the U.K. He also serves as a Member of the National Academy Sciences Working Group on Biological Weapons, the Forum on Microbial Threats of the Institute of Medicine Board on Global Health, and the Institute of Medicine Committee on Advances in Technology and Next Generation Biowarfare Threats. He has published over 350 scientific papers and co-edited 14 books on pharmaceuticals, technology and oncology. He served as Director of SGX Pharmaceuticals, Inc., Maxygen, Inc. and Illumina Inc. He has received honorary degrees in Science and Law for his research contributions and was awarded the rank of Commander of the British Empire by HM Queen Elizabeth II for his services to international health. In 2004, he was named as ‘R&D Scientist of the Year’ by R&D Magazine and in 2006 He received the Einstein award from the Global Business Leadership Council. He has served on government committees for the National Institutes of Health, Office of Technology Assessment (OTA), and the Departments of State, Commerce, and Defense, and is a Member of the U.S. Defense Science Board at the Pentagon. He also has served a number of National Academy panels related to national security. Dr. Poste received a Doctorate in Veterinary' Medicine in 1966 and a Ph.D. in Virology in 1969 from the University of Bristol.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.